200 related articles for article (PubMed ID: 20660830)
1. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
London WB; Frantz CN; Campbell LA; Seeger RC; Brumback BA; Cohn SL; Matthay KK; Castleberry RP; Diller L
J Clin Oncol; 2010 Aug; 28(24):3808-15. PubMed ID: 20660830
[TBL] [Abstract][Full Text] [Related]
2. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.
Ashraf K; Shaikh F; Gibson P; Baruchel S; Irwin MS
Pediatr Blood Cancer; 2013 Oct; 60(10):1636-41. PubMed ID: 23650219
[TBL] [Abstract][Full Text] [Related]
3. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
Kretschmar CS; Kletzel M; Murray K; Thorner P; Joshi V; Marcus R; Smith EI; London WB; Castleberry R
J Clin Oncol; 2004 Oct; 22(20):4119-26. PubMed ID: 15483021
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
Di Giannatale A; Dias-Gastellier N; Devos A; Mc Hugh K; Boubaker A; Courbon F; Verschuur A; Ducassoul S; Malekzadeh K; Casanova M; Amoroso L; Chastagner P; Zwaan CM; Munzer C; Aerts I; Landman-Parker J; Riccardi R; Le Deley MC; Geoerger B; Rubie H
Eur J Cancer; 2014 Jan; 50(1):170-7. PubMed ID: 24021349
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
[TBL] [Abstract][Full Text] [Related]
6. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
Hunold A; Weddeling N; Paulussen M; Ranft A; Liebscher C; Jürgens H
Pediatr Blood Cancer; 2006 Nov; 47(6):795-800. PubMed ID: 16411206
[TBL] [Abstract][Full Text] [Related]
7. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.
Simon T; Längler A; Harnischmacher U; Frühwald MC; Jorch N; Claviez A; Berthold F; Hero B
J Cancer Res Clin Oncol; 2007 Sep; 133(9):653-61. PubMed ID: 17479288
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
Zage PE; Kletzel M; Murray K; Marcus R; Castleberry R; Zhang Y; London WB; Kretschmar C;
Pediatr Blood Cancer; 2008 Dec; 51(6):747-53. PubMed ID: 18704922
[TBL] [Abstract][Full Text] [Related]
9. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Moreno L; Rubie H; Varo A; Le Deley MC; Amoroso L; Chevance A; Garaventa A; Gambart M; Bautista F; Valteau-Couanet D; Geoerger B; Vassal G; Paoletti X; Pearson AD
Pediatr Blood Cancer; 2017 Jan; 64(1):25-31. PubMed ID: 27555472
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
Saylors RL; Stewart CF; Zamboni WC; Wall DA; Bell B; Stine KC; Vietti TJ
J Clin Oncol; 1998 Mar; 16(3):945-52. PubMed ID: 9508177
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212).
Greengard E; Mosse YP; Liu X; Minard CG; Reid JM; Voss S; Wilner K; Fox E; Balis F; Blaney SM; Adamson PC; Weigel BJ
Cancer Chemother Pharmacol; 2020 Dec; 86(6):829-840. PubMed ID: 33095287
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Donfrancesco A; Jenkner A; Castellano A; Ilari I; Milano GM; De Sio L; Cozza R; Fidani P; Deb G; De Laurentis C; Inserra A; Dominici C
Acta Paediatr Suppl; 2004 May; 93(445):6-11. PubMed ID: 15176712
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.
Kushner BH; Kramer K; Meyers PA; Wollner N; Cheung NK
Med Pediatr Oncol; 2000 Nov; 35(5):468-74. PubMed ID: 11070479
[TBL] [Abstract][Full Text] [Related]
15. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.
Kushner BH; Kramer K; Modak S; Qin LX; Cheung NK
Cancer; 2010 Jun; 116(12):3054-60. PubMed ID: 20564411
[TBL] [Abstract][Full Text] [Related]
16. Topotecan plus cyclophosphamide as maintenance chemotherapy for children with high-risk neuroblastoma in complete remission: short-term curative effects and toxicity.
Feng C; Tang S; Wang J; Liu Y; Yang G
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Aug; 33(8):1107-10. PubMed ID: 23996746
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
Donfrancesco A; De Ioris MA; McDowell HP; De Pasquale MD; Ilari I; Jenkner A; Castellano A; Cialfi S; De Laurentis C; Dominici C
Pediatr Blood Cancer; 2010 Jan; 54(1):55-61. PubMed ID: 19821523
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
[TBL] [Abstract][Full Text] [Related]
19. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
De Ioris MA; Castellano A; Ilari I; Garganese MC; Natali G; Inserra A; De Vito R; Ravà L; De Pasquale MD; Locatelli F; Donfrancesco A; Jenkner A
Eur J Cancer; 2011 Mar; 47(4):572-8. PubMed ID: 21112775
[TBL] [Abstract][Full Text] [Related]
20. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
